Targeting the sialoglycan-Siglec axis for cancer immunotherapy

Save Complete Collect Reco
Share on Twitter Copy link Share via
Article
Stanczak et al. showed that hypersialylation on tumor cells promotes polarization of TAMs towards an immunosuppressive phenotype through interactions with Siglec-E, contributing to disease progression and immune escape. Genetic and therapeutic targeting of the sialoglycan-Siglec axis, either through...

Stanczak et al. showed that hypersialylation on tumor cells promotes polarization of TAMs towards an immunosuppressive phenotype through interactions with Siglec-E, contributing to disease progression and immune escape. Genetic and therapeutic targeting of the sialoglycan-Siglec axis, either through desialylation or targeted removal of Siglec-E, promoted the repolarization of TAMs and supported stronger antitumor immune responses, particularly in the setting of immune checkpoint blockade. These results support further investigation of therapeutic desialylation as a potential immunotherapy.

 Show More
Recommended by
Recommendations from around the web and our community.
Carolyn Bertozzi 2 months ago

Nice summary of ⁦@michal_stanczak⁩ and ⁦@LImmunotherapy⁩’s recent publication in ⁦@ScienceTM⁩ on Siglec/sialoglycan axis as target for cancer immune therapy, with the ⁦@Palleon_Pharma⁩ team and us as collaborators. #glycotime